Published in Clinical Oncology Week, July 5th, 2004
The data, presented at the annual meeting of the American Society of Clinical Oncology in New Orleans, Louisiana, demonstrates that in addition to superior overall survival rates, patients also benefited from significantly improved progression-free survival and cancer response rates, as well as a lower rate of severe side effects compared to the standard...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.